Literature DB >> 844917

Relationship of human natural lymphocyte-mediated cytotoxicity to cytotoxicity of breast-cancer-derived target cells.

G B Cannon, G D Bonnard, J Djeu, W H West, R B Herberman.   

Abstract

Mononuclear cells from 115 individuals were tested in a 4-h chromium release assay against two breast-cancer-derived cell lines, G11 and MCF-7, and a myeloid line, K-562, shown previously to be sensitive to natural cytotoxicity. These data were analyzed in a manner designed to detect hyperreactivity against the breast cell lines relative to the level of reactivity against K-562. A high proportion of breast cancer patients were found to be relatively hyperreactive against G11 (12/18 or 67%) and against MCF-7 (10/18 or 56%). Fibroadenoma patients were very similar to the normal females, with 0/11 hyperreactive to G11 and 1/11 (9%) to MCF-7. However, several normal males (7/17 or 41%) were hyperreactive to G11 but not to MCF-7 (2/17 or 12%). Colon cancer and lung cancer patients were also more hyperreactive to G11, 4/8 or 50% and 4/6 or 67%, respectively, than they were to MCF-7, 1/8 or 13% and 1/6 or 17%, respectively. Only fibrocystic patients resembled the breast cancer patients, with some but not as many individuals being hyperreactive to G11 (3/8 or 38%) and to MCF-7 (2/8 or 25%). With another group of individuals reproducibility of the method was demonstrated, with only 1/14 or 7% of normal females and 12/17 or 70% of breast cancer patients being hyperreactive to G11. Thus, natural cytotoxicity toward K-562 can be related to breast cancer-associated cytotoxicity toward MCF-7 in a way that distinguishes a majority of breast cancer patients specifically from other groups of individuals.

Entities:  

Mesh:

Year:  1977        PMID: 844917     DOI: 10.1002/ijc.2910190409

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Natural killer cell activities of patients with breast cancer against different target cells.

Authors:  G Hamilton; A Reiner; B Teleky; E Roth; R Kolb; J Spona; R Jakesz
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 2.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

3.  In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer.

Authors:  E Robinson; D Rubin; T Mekori; R Segal; S Pollack
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

4.  Relationship of natural killer cytotoxicity to clinical and biochemical parameters of primary human breast cancer.

Authors:  A Fulton; G Heppner; L Roi; L Howard; J Russo; M Brennan
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

Review 5.  Differentiation of the mammary gland and susceptibility to carcinogenesis.

Authors:  J Russo; L K Tay; I H Russo
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

Review 6.  Natural killer cells in human solid tumors.

Authors:  M Introna; A Mantovani
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Cytotoxic immune response of meningioma patients towards allogeneic and autologous tumour cells before and after surgery.

Authors:  H W Pees
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

8.  Separation of spontaneous-killing effector populations by target preference.

Authors:  R A Knight; P Fitzharris
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.